SSY Group Limited Receives NMPA Approval for Furosemide Bulk Drug Registration

Key Highlights for Investors

• Regulatory Milestone Achieved: SSY Group Limited (“the Company”) has secured approval from the National Medical Products Administration of China (NMPA) for the registration of Furosemide as a bulk drug, enabling its use in market preparations.
• Expansion of Product Portfolio: This registration complements previous NMPA approvals for Furosemide Tablet and Furosemide Injection, which were announced by the Company on 30 June 2025 and 27 December 2024.
• Broad Therapeutic Applications: Furosemide is indicated for a wide range of conditions including edema, hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), acute drug poisoning (e.g., barbiturate poisoning), and prevention of acute kidney failure.
• Potential Share Price Impact: The approval of Furosemide as a bulk drug strengthens the Group’s competitive position in the pharmaceutical sector, enhances its product pipeline, and may positively influence future revenues and profitability—a point of direct interest to shareholders and potential investors.

Details of the Development

The Board of Directors of SSY Group Limited has announced that the Company has obtained registration approval from the NMPA for Furosemide as a bulk drug. This significant regulatory achievement follows earlier approvals for the production and registration of Furosemide in both tablet and injection forms. The latest approval allows SSY Group to manufacture and market Furosemide in bulk quantities for pharmaceutical preparations, broadening its market reach and product offerings.

Furosemide is a widely used medication with multiple clinical indications. Its main uses include the treatment of various diseases associated with edema, management of hypertension, correction of abnormal serum potassium and calcium levels (hyperkalemia and hypercalcemia), treatment of dilutional hyponatremia and SIADH, as well as emergency interventions for acute drug poisoning and the prevention of acute kidney failure. The expansion into bulk drug production positions SSY Group to capitalize on the growing demand for this essential medicine, both domestically in China and potentially in international markets.

This voluntary announcement underscores SSY Group’s ongoing commitment to expanding its pharmaceutical portfolio and increasing transparency with shareholders and the investment community. The move aligns with the Group’s strategic growth objectives and could be seen as a catalyst for future business development and revenue growth.

Board and Corporate Governance Update

The announcement, signed by Executive Director and Company Secretary Chow Hing Yeung and dated 21 April 2026, confirms the current composition of the Board. The Board consists of Executive Directors Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong; Non-Executive Director Mr. Liu Wenjun; and Independent Non-Executive Directors Mr. Wang Yibing, Mr. Chow Kwok Wai, and Mr. Jiang Guangce.

What Shareholders Need to Know

• Obtaining NMPA approval for Furosemide bulk drug registration is a potentially price-sensitive development, as it represents an expansion of the Group’s product licenses and could lead to increased production capacity and market share.
• The announcement is intended to keep shareholders and potential investors informed of significant business developments that may affect the company’s valuation.
• Further commercial success of Furosemide, given its broad clinical applications, may have a positive impact on SSY Group’s financial performance and share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and seek independent professional advice before making any investment decisions. The information provided is based on the latest announcement from SSY Group Limited as of 21 April 2026, and there is no guarantee of future company performance or share price movement.

View SSY GROUP Historical chart here